Hospital
Tenet Hospitals Limited
Tenet Hospitals Limited was paid $2.58M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoTENET HOSPITALS LIMITED
EL PASO, TX 79902
EL PASO, TX 79902
33aNPI1215969787assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.58M
24GClaims68,782
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#45 of 109
Median peer was paid$1.15M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,773 | $1.33M | |
| 2019 | 2,137 | $54K | |
| 2020 | 3,355 | $53K | |
| 2021 | 12,098 | $255K | |
| 2022 | 13,600 | $353K | |
| 2023 | 12,298 | $344K | |
| 2024incomplete | 8,521 | $197K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 1,951 | 1,783 | $533K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 2,329 | 2,168 | $520K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 2,081 | 1,995 | $397K |
| 80053 | Comprehensive metabolic panel | 5.1% | 6,053 | 5,198 | $133K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4.3% | 957 | 949 | $112K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.7% | 2,696 | 2,375 | $97K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 5,681 | 4,727 | $66K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 295 | 280 | $45K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.5% | 2,009 | 1,695 | $38K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 1,129 | 985 | $35K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 791 | 729 | $33K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 298 | 277 | $32K |
78 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 180 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,772 | $26K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,093 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,369 | $24K |
| 81001 | <1% | 2,975 | $24K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 386 | $21K |
| 80061 | Lipid panel | <1% | 1,070 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 467 | $19K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 42 | $18K |
| 84484 | <1% | 1,133 | $18K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 591 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 672 | $16K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,635 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 660 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 55 | $14K |
| 80050 | General health panel | <1% | 163 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,230 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 807 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 924 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 177 | $9K |
| 85610 | <1% | 2,055 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 68 | $9K |
| 83690 | <1% | 805 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,146 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,357 | $8K |
| 85027 | <1% | 1,479 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,012 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 348 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 159 | $7K |
| 83880 | <1% | 207 | $6K | |
| 86403 | <1% | 267 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 578 | $6K |
| 85730 | <1% | 1,253 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 82 | $5K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,721 | $5K |
| J3490 | Unclassified drugs | <1% | 750 | $5K |
| 83735 | <1% | 556 | $4K | |
| 84703 | <1% | 255 | $4K | |
| 76641 | <1% | 41 | $4K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 70 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 450 | $4K |
| 0002A | <1% | 116 | $4K | |
| 73130 | <1% | 36 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 595 | $3K |
| 81025 | <1% | 311 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 372 | $3K |
| 0001A | <1% | 128 | $3K | |
| 77080 | <1% | 51 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 30 | $2K |
| 82962 | <1% | 2,110 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 100 | $2K |
| 83605 | <1% | 123 | $2K | |
| 84439 | <1% | 134 | $2K | |
| 73610 | <1% | 13 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 620 | $2K |
| 87420 | <1% | 27 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,517 | $2K |
| 82150 | <1% | 109 | $1K | |
| 87077 | <1% | 175 | $1K | |
| 87186 | <1% | 83 | $1K | |
| 82947 | <1% | 15 | $915.61 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 59 | $823.46 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 78 | $700.80 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 15 | $687.55 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 13 | $536.60 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 611 | $454.86 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,011 | $414.40 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 25 | $372.87 |
| A9270 | Non-covered item or service | <1% | 732 | $251.80 |
| 87806 | <1% | 25 | $227.56 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 60 | $204.65 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 38 | $181.55 |
| 86140 | <1% | 13 | $50.55 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 13 | $37.45 |
| 85652 | <1% | 14 | $26.38 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 44 | $17.20 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSILLO, MAYRA (CFO)